4SC-201 (Resminostat) in Advanced Colorectal Carcinoma
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the Maximum Tolerated Dose (MTD) of 4SC-201
(Resminostat) in combination with FOLFIRI and whether 4SC-201 (Resminostat) is effective and
safe in combination FOLFIRI versus FOLFIRI alone in the treatment of advanced colorectal
carcinoma.